Welcome to our dedicated page for Ashland news (Ticker: ASH), a resource for investors and traders seeking the latest updates and insights on Ashland stock.
Ashland Inc. reports developments for a global additives and specialty ingredients business serving pharmaceuticals, personal care, food and beverage, architectural coatings, construction, energy and other industrial markets. Company updates commonly cover quarterly results and outlook, segment demand across Life Sciences, Personal Care, Specialty Additives and Intermediates, pricing actions tied to raw-material and logistics conditions, and capital returns through common-stock dividends.
Other Ashland news includes product and regulatory developments for specialty ingredients such as agrimer™ eco-coat polymer seed coating from the Transformed Vegetable Oils technology platform, as well as distribution relationships for cellulose ethers and PVPP in food and beverage applications.
Ashland (NYSE: ASH) announced the appointment of Alessandra Faccin as senior vice president and general manager of its Life Sciences division, effective June 10, 2024. Faccin brings over 20 years of experience in global industrial and manufacturing industries, having most recently served as president of Sealed Air , Asia Pacific. She has a broad financial background and has held leadership roles at Dow Chemical and Rohm & Haas. Faccin's educational background includes a Bachelor's in business administration from Fundação Getúlio Vargas and an Executive MBA from Universidade de São Paulo, along with certifications from The Wharton School and Villanova University.
Ashland Inc. (NYSE: ASH) appoints Ashish K. Kulkarni, CEO of Kebotix, to its Board of Directors. Kulkarni brings vast experience from leading companies, enhancing innovation, growth, and profitability. The Board expands to 11 members with his addition.
Ashland Inc. (ASH) board of directors has approved a quarterly dividend of $0.405 per share, marking a five percent increase from the prior quarter. The dividend will be paid on June 15, 2024, to stockholders on record as of June 1, 2024. As of April 30, 2024, there were 50,128,349 shares of Ashland common stock outstanding.
Turnspire Capital Partners has announced the acquisition of the nutraceuticals business of Ashland Inc. The acquisition includes Ashland Nutraceuticals, a leading provider of nutrition ingredients and custom formulation services for the nutrition market. Ashland Nutraceuticals has approximately 500 employees across four production facilities in the US and Mexico. The transaction is expected to be completed in the third quarter of 2024.
Ashland Inc. (NYSE: ASH) has signed a definitive agreement to sell its nutraceuticals business to Turnspire Capital Partners The transaction is set to close in the third quarter of 2024. Ashland's nutraceuticals business offers active ingredients and formulation aids to nutritional product companies, alongside custom formulation and contract manufacturing services. The deal highlights the business's strong portfolio and capabilities.
Ashland Inc. (NYSE: ASH) reported financial results for the second quarter of fiscal year 2024, with sales at $575 million, down five percent from the prior-year quarter. Net income reached $120 million, or $2.39 per diluted share. Adjusted EBITDA was $126 million, and cash flows from operating activities were $54 million. The company's outlook for the third quarter and full-year fiscal 2024 shows an optimistic perspective on the demand normalization in key segments like Personal Care and Specialty Additives.
Summary not available.
Summary not available.
Summary not available.
Summary not available.